Fidia S.p.A. (BIT:FDA)
Italy
· Delayed Price · Currency is EUR | Market Cap | 3.13M |
| Revenue (ttm) | 17.53M |
| Net Income (ttm) | -9.30M |
| Shares Out | 7.47M |
| EPS (ttm) | -32.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,266 |
| Average Volume | 565,560 |
| Open | 0.4300 |
| Previous Close | 0.4192 |
| Day's Range | 0.3970 - 0.4300 |
| 52-Week Range | 0.2000 - 74.0000 |
| Beta | 0.06 |
| RSI | 41.76 |
| Earnings Date | Sep 11, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
RFK Jr’s vaccine panel recommends new RSV treatment for infants
Move comes after health secretary replaced advisory board with ideological allies and several vaccine skeptics Health secretary Robert F Kennedy Jr ’s reconstituted vaccine advisory panel recommended ...
Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss new members of the CDC's new vaccine advisory board, what to expect in the new vaccine agenda, and more.
Scarcity and Opportunity Amid Biotech’s Tough Times
Dear reader, 2025 hasn't been an entirely bright year for the U.S. stock market. IPO opportunities have dried up, the FDA is experiencing considerable turmoil, and significant...
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, I...
Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped.
Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.
Crude Oil Rises Sharply; Torrid Holdings Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Wednesday. The Dow traded down 0.18% to 43,011.70 while the NASDAQ gained 0.20% to 19,953.27. The S&P 5...
Plus Therapeutics rises after FDA clearance to begin Reyobiqtm trial
Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development tools Designation recognizes the potential of detalimogene to address significant unmet need BOSTON...
Actress Lingling Kwong apologises for food brand shortcomings
Popular actress Lingling Kwong has apologised to customers after her Kwong Pastry egg roll brand faced criticism over missing Thai Food and Drug Administration (FDA) approval labels and poor customer ...
Top stocks in focus on June 25: JB Chemicals, Infosys, PTC Industries, HAL, IRCTC, and more
The Indian stock market is set for an eventful session on Wednesday, June 25, with several companies announcing fresh developments that could draw investor attention. Here’s a look at key corporate ne...
FDA's Makary sought to reject KalVista’s drug: report
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy
Capricor Therapeutics Inc (NASDAQ: CAPR) on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate for the tr...
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth darling Hims & Hers Health Inc (NYSE: HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE: NVO) ended their relationship – and it wasn't amicable. But is the plunge...
General Mills Q4 Preview: Will Pet Food, Dye-Free Push Win Over Investors?
Food company General Mills Inc. (NYSE: GIS) will likely highlight its recent news of eliminating food dyes in its products in future years when the company reports fourth-quarter financial results be...
GSK gets FDA nod for Benlysta autoinjector in lupus
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ha...
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated...
Gland Pharma gets EIR from US FDA for Visakhapatnam JNPC facility
Gland Pharma has announced that it has received the Establishment Inspection Report (EIR) from the US FDA for its sterile API manufacturing facility located at JNPC, Visakhapatnam. This follows the su...
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in Atraumatic Sutureless Peripheral Nerve Repair
This regulatory milestone marks TISSIUM’s entry into the U.S. market and establishes the foundation of the TISSIUM polymer platform for atraumatic tissue repair Paris, France, Cambridge, USA, June 24,...
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and AstraZeneca's DATROWAY in less than six months DAT...
Why Is Capricor Therapeutics Stock Trading Lower On Monday?
Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per data from Benzinga Pro . Accord...
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel ODay joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importanc...